Skip to main content
SpringerLink
Log in

Diabetic Dyslipidemia

  • Chapter
  • First Online:
Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome

Part of the book series: Current Clinical Practice ((CCP))

Abstract

Insulin Resistance represents the central unifying principle of the clustering of abnormalities defining the Metabolic Syndrome and the hallmark of type-2 diabetes. A review of data from NHANES III indicated that 85% of individuals older than 50 with the Metabolic Syndrome were insulin resistant [1]. Even in the absence of over hyperglycemia, or abnormal glucose tolerance, insulin resistance is associated with abnormal lipid and lipoprotein metabolism, characterized by elevated triglycerides and low plasma levels of HDL cholesterol with an increase in the production of small, dense LDL (low density lipoprotein) particles as outlined in Table11. However, total cholesterol and LDL levels are comparable to individuals who are not diabetic, underscoring the importance of quantitative and qualitative lipid measurement, including total particle number and size, to accurately assess cardiovascular risk.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Miranda PJ, DeFronzo RA, Califf RM, Guyton J. Metabolic syndrome: definition, pathophysiology, and mechanism. Am Heart J. 2005;149:33–45.

    Article  CAS  PubMed  Google Scholar 

  2. Cordero A, LaClaustra M, Leon M, Grima A, Casanovas J, Luengo E, del Rio A. Prehypertension is associated with insulin resistance; the MESYAS registry. Am J Hypertens. 2006;19(2):189–196.

    Article  CAS  PubMed  Google Scholar 

  3. NCEP Expert Panel. Executive summary of the third report of the National Cholesterol Education Program. JAMA. 2001;285:2486–2497.

    Article  Google Scholar 

  4. Shepherd J, Barter P, Carmena R. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the treating to new targets (TNT) study. Diabetes Care. 2006;29:1220–1226.

    Article  CAS  PubMed  Google Scholar 

  5. Tung P, Wiviott S, Cannon C, Murphy S, McCabe C, Gibson M. Seasonla variation in lipids following acute coronary syndrome on fixed doses of Pravastatin or Atorvastatin from the PROVE IT-TIMI study. Am J Cardiol. 2009;103:1056–1060.

    Article  CAS  PubMed  Google Scholar 

  6. Robins S, Collins D, Wittes J, Papademetriou V. VA-HIT, a randomized trial. JAMA. 2001;285: 1585–1591.

    Article  CAS  PubMed  Google Scholar 

  7. Lange P, Parner J, Schnohr P, Jensen G. The copenhagen city heart study. Eur Respir J. 2002;20: 1406–1412.

    Article  CAS  PubMed  Google Scholar 

  8. Nordestgaard B, Benn M, Schnohr P, Hansen A. Nonfasting triglycerides and risk for myocardial infarction, ischemic heart disease and death. JAMA. 2007;298:299–308.

    Article  CAS  PubMed  Google Scholar 

  9. Best JD, et al. Diabetic dyslipidemia, current treatment and recommendations. Drugs. 2000;59:1101–1111.

    Article  CAS  PubMed  Google Scholar 

  10. Johnson R, McNutt P, MacMahon S, Robson R. The use of the Friedewald formula to estimate LDL. Clin Chem. 1997;43:2183–2184.

    CAS  PubMed  Google Scholar 

  11. St. Pierre A, Cantin B, Dagenais G, Mauriege B. Low density lipoprotein subfractions and the long term risk of ischemic heart disease in men. The Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol. 2005;25:553.

    Google Scholar 

  12. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care. 2000;23(suppl 1):S57–S60.

    Google Scholar 

  13. Steiner G. Treating lipid abnormalities in patients with type 2 diabetes mellitus. Am J Cardiol. 2001;88(suppl):37N–40N.

    Article  CAS  PubMed  Google Scholar 

  14. Bush T, Barrett-Connor E, Cowan L, Criqui M. The lipid research clinics follow up study. Circulation. 1987;75:1102–1109.

    Article  CAS  PubMed  Google Scholar 

  15. The Diabetes Atorvastatin Lipid Intervention group. The DALI study. Diabetes Care. 2001;24(8): 1335–1341.

    Article  Google Scholar 

  16. Canner PL, Furberg CD, McGovewrn ME. Benefits of niacin in patients with and without the metabolic syndrome. Am J Cardiol. 2006;97:477–479.

    Article  CAS  PubMed  Google Scholar 

  17. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360–381.

    Article  Google Scholar 

  18. Armani AM, Toth PP. Colesevelam hydrochloride in the management of dyslipidemia. Expert Rev Cardiovasc Ther. 2006;4(3):283–291.

    Article  CAS  PubMed  Google Scholar 

  19. Manghat P, Wierzbicki AS. Colesevelam hydrochloride: a specifically engineered bile acid sequestrant. Future Lipidol. 2008;3:237–253.

    Article  CAS  Google Scholar 

  20. Toth PP, Dayspring TD, Pokrywka GS. Drug therapy for hypertriglyceridemia: fibrates and omega-3 fatty acids. Curr Atheroscler Rep. 2009;11(1):71–79.

    Article  CAS  PubMed  Google Scholar 

  21. Vakkillainen J, Steiner G, Ansquer J. Fenofibrate lowers triglycerides and increases LDL particle number in subjects with type-2 diabetes. Diabetes Care. 2002;25(3):627–628.

    Article  Google Scholar 

  22. Rubins HB, Robins SJ, Collins D. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. Veterans Affairs High Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410–418.

    Article  CAS  PubMed  Google Scholar 

  23. Hartweg J, Perera R, Montori VM, Dineen SF, Neil A, Farmer AJ. Omega-3 Polyunstaurated fatty acids for diabetes. Cochrane Database Syst Rev. 2010;(4):CD003205.

    Google Scholar 

  24. Pan J, et al. Niacin treatment of the atherogenic profile and Lp(a) in diabetes. Diabetes Obes Metab. 2002;4:255–261.

    Article  CAS  PubMed  Google Scholar 

  25. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinier JA, Tan MH, The GLAI Investigators. A comparison of the lipid and glycemic effects of pioglitazone and rosiglitazone in type-2 diabetics and dyslipidemia. Diabetes Care. 2005;28:1547–1554.

    Article  CAS  PubMed  Google Scholar 

  26. Khan M, Berhanu P, Perex A, Demisse S, Fleck P, Kupfer S. Effects of pioglitazone in combination with stable statin therapy on lipid levels in subjects with type-2 diabetes and dyslipidemia when switched from rosiglitazone (The COMPLEMENT trial). Diabetes. 2005;54(suppl 1):A137.

    Google Scholar 

  27. Szapary P, Bloedon LT, Samaha FF, Duffy D, Reilly M, Chittams J, Rader D. Effects of pioglitazone on lipoproteins, inflammatory markers and adipokines in non diabetic patients with metabolic syndrome. Arterioscler Throm Vasc Biol. 2006;26:182.

    Article  CAS  Google Scholar 

  28. Jones PH, Davidson MH, Stein EA. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92:152–160.

    Article  CAS  PubMed  Google Scholar 

  29. Tricor Package Insert. North Chicago: Abbott Laboratories; 2001.

    Google Scholar 

  30. Jones PH, Davidson MH, et al. Comparison of the efficacy and safety of rosuvastatin vs. atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol. 2003;92:152–160.

    Article  CAS  PubMed  Google Scholar 

  31. Capuzzi DM, Morgan JM, Carey CM. Rosuvastatin alone or with extended release niacin; a new therapeutic option for patients with combined hyperlipidemia. Prev Cardiol. 2004;7:176–181.

    Article  CAS  PubMed  Google Scholar 

  32. Ridker PM, The JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low density lipoprotein cholesterol and elevated high sensitivity C-reactive protein. Circulation. 2003;108:2292–2297.

    Article  PubMed  Google Scholar 

  33. Scandinavian Simvastatin Survival Study Investigators. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The 4S Study. Lancet. 1994;344:1383–1389.

    Google Scholar 

  34. The Long Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–1357.

    Google Scholar 

  35. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother. 2001;35:908–917.

    Article  CAS  PubMed  Google Scholar 

  36. Prucksaritanont T, Zhao JJ, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. JPET. 2002;301:1042–1051.

    Article  Google Scholar 

  37. Downs JR, Clearfield M, Weis S. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615–6122.

    Article  CAS  PubMed  Google Scholar 

  38. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.

    Article  Google Scholar 

  39. Grundy SM, Vega LG, Yuan Z. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol. 2005;95:462–468.

    Article  CAS  PubMed  Google Scholar 

  40. Vrecer M, Turk S, et al. Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Int J Clin Parmacol Ther. 2003;41:567–577.

    CAS  Google Scholar 

  41. Hites RA, Foran JA, Carpenter DO, Hamilton MC, Knuth BA, Schwager SJ. Risk global assessment of organic contaminants in farmed salmon. Science. 2004;303:226–229.

    Article  CAS  PubMed  Google Scholar 

  42. Davidson M. Omega-3 fatty acids enhance statin lipid lowering effects. The COMBOS trial. Clin Ther. 2007;29:1354–1357.

    Article  CAS  PubMed  Google Scholar 

  43. Brown BG, Zhao X-Q, Chait A. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–1592.

    Article  CAS  PubMed  Google Scholar 

  44. Elam MB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT study: a randomized trial. JAMA. 2000;284: 1263–1270.

    Article  CAS  PubMed  Google Scholar 

  45. Zhao XQ. Simvastatin plus niacin protect against atherosclerosis progression and clinical events in coronary artery disease patients with metabolic syndrome. Am Coll Cardiol. 2002;39(suppl A):242A.

    Article  Google Scholar 

  46. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischemic. Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223:405–418.

    Article  CAS  PubMed  Google Scholar 

  47. Brown G, Albers JJ, Fisher LD. Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289–1298.

    Article  CAS  PubMed  Google Scholar 

  48. Morris MC, Sacks F, et al. Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation. 1993;88:523.

    Article  CAS  PubMed  Google Scholar 

  49. The NCEP Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. JAMA. 2001;285:2486–2497.

    Google Scholar 

  50. Mykkanen L, Laakso M, Pentilla I, Pyorala K. Asymptomatic hyperglycemia and cardiovascular risk factors in the elderly. Atherosclerosis. 1991;88:153–161.

    Article  CAS  PubMed  Google Scholar 

Supplementary Readings

  • Carswell CL, Plosker GL, et al. Rosuvastatin. Drugs. 2002;62:2075–2085.

    Article  CAS  PubMed  Google Scholar 

  • Castelli WP. Cholesterol and lipids in the risk of coronary artery disease – the Framingham Heart Study. Can J Cardiol. 1988;4(suppl A):5A–10A.

    PubMed  Google Scholar 

  • Castelli WP. Cardiovascular disease and multifactorial risk: challenge of the 1980s. Am Heart J. 1983;106:1191–1200.

    Article  CAS  PubMed  Google Scholar 

  • Despres JP. Increasing high density lipoprotein cholesterol, an update on fenofibrate. Am J Cardiol. 2001;88(suppl):30N–36N.

    Article  CAS  PubMed  Google Scholar 

  • Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin dependent diabetes mellitus. JAMA. 1990;264:723–726.

    Article  CAS  PubMed  Google Scholar 

  • Goldberg IJ. Diabetic dyslipidemia, causes and consequences. J Clin Endocrinol Metab. 2001;86: 965–971.

    Article  CAS  PubMed  Google Scholar 

  • Goldberg RB, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose intolerant myocardial infarction survivors with average cholesterol levels: CARE trial. Circulation. 1998;98:2513–2519.

    Article  CAS  PubMed  Google Scholar 

  • Koskinen P, et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 1992;15:820–825.

    Article  CAS  PubMed  Google Scholar 

  • Langtry HD, Markham A. Fluvastatin, a review of it use in lipid disorders. Drugs. 1999;57:583–606.

    Article  CAS  PubMed  Google Scholar 

  • McKenney J. Combination therapy for elevated low density lipoprotein cholesterol. The key to coronary artery disease risk reduction. Am J Cardiol. 2002;90(suppl):8K–20K.

    Article  CAS  PubMed  Google Scholar 

  • Miettinen TA, Taskinen MR, et al. Glucose tolerance and plasma insulin in man during acute and chronic administration of nicotinic acid. Acta Med Scand. 1969;186:247–253.

    Article  CAS  PubMed  Google Scholar 

  • Rubins HB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol: VA-HIT Study group. N Engl J Med. 1999;341: 410–418.

    Article  CAS  PubMed  Google Scholar 

  • Steiner F. Lipid intervention trials in diabetes. Diabetes Care. 2001;23(suppl 2):B49–B53.

    Google Scholar 

  • Superko HR, Krauss RM. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis. 1992;95:69–76.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Pennsylvania Health System Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA

    Ronald A. Codario MD, FACP (Clinical Instructor in Medicine)

Authors
  1. Ronald A. Codario MD, FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Diplomate American Board of Internal Medicine

Diplomate American Board of Clinical Lipidology

Diplomate American Board of Vascular Medicine

Clinical Hypertension Specialist (American Society of Hypertension Certified)

Vascular Ultrasound (American Registry of Diagnostic Sonography Certified)

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Codario, R.A. (2011). Diabetic Dyslipidemia. In: Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome. Current Clinical Practice. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-441-8_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-441-8_11

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60327-440-1

  • Online ISBN: 978-1-60327-441-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation